In an effort to promote greater understanding of Temporomandibular Disorders (TMD) and to develop safe and effective evidence-based diagnostics and treatments. The TMJ Association promotes and encourages basic and clinical research on TMD. We invite you to view a listing of the latest National Institutes of Health (NIH) funding opportunities for scientists interested in advancing TMJ research.
The purpose of this funding opportunity announcement (FOA) is to encourage research on mechanisms underlying the manifestations of sex-based differences in Dental, Oral, and Craniofacial (DOC)-related diseases and conditions. Specifically, this initiative encourages studies aimed at understanding immune reactivity, genetic variation, environmental triggers, aging, and hormonal changes as they affect sex-based differences in DOC-related diseases and conditions including, but not limited to, Sjögren’s Syndrome (SS), orofacial pain, temporomandibular joint (TMJ) disorder (TMD), salivary gland tumors, and human papillomavirus (HPV)-associated oropharyngeal cancers.
The FaceBase Consortium is developing a variety of comprehensive datasets on craniofacial development that are available to the wider scientific community at www.facebase.org. This funding opportunity announcement (FOA) will support meritorious research projects that conduct secondary data analyses of these FaceBase datasets relevant to craniofacial development, human craniofacial conditions or traits, and animal models of those craniofacial conditions. Informatics projects that integrate data from multiple FaceBase datasets are especially encouraged.
This Funding Opportunity Announcement encourages research to address gaps in our knowledge of how best to treat oral diseases of patients with systemic diseases or conditions known to compromise oral health, to identify factors predictive of treatment outcomes within patient groups, and to generate evidence for more precise dental treatment guidelines tailored to patient needs. It is expected that research applications will propose studies utilizing established cohorts of individuals with the disease of interest.
The purpose of this initiative is to encourage interdisciplinary research to decrease symptom burden and enhance health-related quality of life (HRQL) in persons with chronic illness through a) increasing knowledge of the biological mechanisms of symptoms and b) promoting innovative, cost-effective, targeted interventions to prevent, manage or ameliorate these symptoms.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch. Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation. This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs). The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities. Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.
The OPPERA study has demonstrated that pelvic pain is moderately associated with TMD. Given this relationship we are publicizing this research opportunity.
The Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), invites research grant applications to conduct fundamental basic and translational research focused on urologic chronic pelvic pain syndrome.
The NIDDK has allocated up to $2 million to solicit basic and translational studies from investigators NEW to the MAPP Network that will be conducted in collaboration with the existing MAPP Network and in support of the Network's goals of informing future clinical investigations and ultimately improving clinical management of urologic chronic pelvic pain syndrome patients.
Applications may request up to $500,000 and will be supported through sub-contracts to the MAPP Network's Data Coordination Core (DCC) at the University of Pennsylvania. The application receipt date is June 15, 2015. For additional information see the MAPP Network website (http://www.mappnetwork.org/)
Its purpose is to expand contemporary, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. The goal is to advance knowledge of the immunological basis of dental, oral, and craniofacial diseases, and to develop tools and technologies for precise modulation of the immune system to restore or maintain health. The expectation is that new knowledge derived from this research will facilitate development of novel immunomodulatory therapies to prevent disease onset or reverse disease progression.
In orofacial pain, peripheral tissue damage or nerve injury stimulates local and systemic immune responses interfacing with the central nervous system (CNS), and this process is likely to be involved in the transition of acute to chronic pain as well as in the persistence of chronic pain
The purpose of this funding opportunity is to support research that will provide a better understanding of total joint structure and mechanics including the interactions of the skeletal, muscular, nervous, immune, and circulatory systems and how these many tissues that function together go awry in disease.
The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN participants receive intellectual property rights to drug candidates developed through the program.
The purpose of this Funding Opportunity Announcement (FOA)is to encourage research into dental, oral, and craniofacial diseases and disorders for which there is evidence for genetic heritability but for which we do not have a strong understanding of the genetics/genomics of the disease or disorder. Applicable areas of investigation include identification of promising areas of the genome, and characterization and elucidation of the function(s) of genetic variants that affect disease risk in humans. The ultimate goal of these studies will be to drive development of effective diagnostic, therapeutic, and preventive approaches.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions. The main objective of this FOA is the formation of research groups with interests bridging expertise in pain mechanisms with translational and clinical expertise to address important unresolved questions about overlapping pain conditions. Applicants are encouraged to leverage existing and develop new resources pertinent to the study of these conditions. Applicants are encouraged to include researchers with complementary expertise from outside the pain field in their research teams who will enhance the breadth of research and understanding of comorbid chronic pain conditions.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.
The Biomarkers Consortium, a research partnership managed by the Foundation for the National Institutes of Health, is soliciting concepts for biomarker projects. Researchers are encouraged to submit project concepts online at http://www.biomarkersconsortium.org. If a concept is approved for development by the consortium, the Foundation for NIH will seek funds to support the project.
The consortium is a large-scale, public-private research partnership formed in 2006 to identify and qualify biomarkers. It encourages participation by academia, government, industry, patient advocacy groups and other non-profit organizations. In addition to the Foundation for NIH, founding members of the consortium include the NIH, the Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America.
Information about the Foundation for NIH is available at http://www.fnih.org.